We are live on
!
Find out more
RVM
RiverVest Venture Management Portfolio holdings
AUM
$6.84M
1-Year Est. Return
7.71%
This Fund
S&P 500
This Quarter
Est. Return
+65.77%
1 Year Est. Return
-7.71%
3 Year Est. Return
-16.51%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$910M
AUM Growth
–
Cap. Flow
+$703M
Cap. Flow
% of AUM
77.21%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALLK
Allakos
ALLK
|
+$598M |
| 2 |
SPRB
Spruce Biosciences
SPRB
|
+$47.5M |
| 3 |
Mirum Pharmaceuticals
MIRM
|
+$37.8M |
| 4 |
VAPO
Vapotherm, Inc. Common Stock
VAPO
|
+$16.9M |
| 5 |
OTIC
Otonomy, Inc.
OTIC
|
+$2.28M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
JDR
KIM
ACM
HVM
BGC
QC
CU
PWA
RiverVest Venture Management's Q4 2020 Portfolio in Review
Q4 2020 is the first quarter with a 13F filing on record for RiverVest Venture Management, which disclosed 5 positions worth $910M. Its ten largest holdings account for 100% of the portfolio.
Its largest position is Allakos: 5,750,506 shares worth $805M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- RiverVest Venture Management's largest Q4 2020 buy was Allakos: 5,750,506 shares worth $805M.
- RiverVest Venture Management's ten largest holdings make up 100% of its $910M portfolio in Q4 2020.
- RiverVest Venture Management disclosed 5 positions in Q4 2020, its first 13F filing on record.
Based on RiverVest Venture Management's 13F filing for Q4 2020, filed 11 Aug 2021.